Gossamer Bio, Inc. (GOSS) vs Kalaris Therapeutics Inc. (KLRS)

Gossamer Bio, Inc. and Kalaris Therapeutics Inc. are both Biotechnology companies. Gossamer Bio, Inc. and Kalaris Therapeutics Inc. are of similar size ($67.1M and $66.8M). Kalaris Therapeutics Inc. has the higher net margin (0.00% vs −235.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Kalaris Therapeutics Inc. leads on 8 and Gossamer Bio, Inc. on 4.

Valuation

Metric GOSS KLRS Biotechnology median
P/E n/m n/m 7.88
P/S 0.82 n/m 11.47
P/B n/m 1.20 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.09 0.74
EV/Sales 4.16 n/m 10.73
Earnings yield (416.82%) (69.18%) (28.84%)
Free cash flow yield (371.79%) (58.83%) (23.03%)

Profitability

Metric GOSS KLRS Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (311.70%) 0.00% 0.00%
Net margin (235.00%) 0.00% 0.00%
Free cash flow margin (305.19%) 0.00% 0.00%
Return on equity 178.72% (79.91%) (57.72%)
Return on assets (78.81%) (46.02%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GOSS KLRS Biotechnology median
Revenue growth (TTM) 32.43% — 5.64%
EPS growth (last fiscal year) (200.00%) 94.50% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GOSS KLRS Biotechnology median
Debt to equity (0.38) 0.00 0.00
Current ratio 0.53 10.98 4.73
Net debt to EBITDA (0.35) 2.54 0.96

Dividend

Metric GOSS KLRS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric GOSS KLRS Biotechnology median
Market cap 66.79m 67.05m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack